Institution
Jefferson College
Education•Hillsboro, Missouri, United States•
About: Jefferson College is a education organization based out in Hillsboro, Missouri, United States. It is known for research contribution in the topics: Health care & MEDLINE. The organization has 434 authors who have published 384 publications receiving 10913 citations. The organization is also known as: JeffCo.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
Abstract: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P = 0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P = 0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P = 0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with highdose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P = 0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P = 0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P = 0.32). CONCLUSIONS Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)
3,988 citations
••
TL;DR: The potential role of epigenetic factors in the etiology of ASD is examined, particularly because epigenetic modifications do not change the primary genomic sequence, allowing risk epialleles to evade detection using standard screening strategies.
Abstract: The autism spectrum disorders (ASD) comprise a complex group of behaviorally related disorders that are primarily genetic in origin. Involvement of epigenetic regulatory mechanisms in the pathogenesis of ASD has been suggested by the occurrence of ASD in patients with disorders arising from epigenetic mutations (fragile X syndrome) or that involve key epigenetic regulatory factors (Rett syndrome). Moreover, the most common recurrent cytogenetic abnormalities in ASD involve maternally derived duplications of the imprinted domain on chromosome 15q11-13. Thus, parent of origin effects on sharing and linkage to imprinted regions on chromosomes 15q and 7q suggest that these regions warrant specific examination from an epigenetic perspective, particularly because epigenetic modifications do not change the primary genomic sequence, allowing risk epialleles to evade detection using standard screening strategies. This review examines the potential role of epigenetic factors in the etiology of ASD.
332 citations
••
TL;DR: Differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC.
269 citations
••
263 citations
••
TL;DR: The HF-ACTION trial is designed to definitively assess the effect of exercise training on the clinically relevant end points of mortality, hospitalization, and quality of life in patients with heart failure.
228 citations
Authors
Showing all 437 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stephen D. Silberstein | 100 | 536 | 39971 |
David L. Paul | 85 | 242 | 28282 |
Irving M. Shapiro | 78 | 319 | 28558 |
Vincenzo Berghella | 75 | 603 | 19206 |
Timothy M. Block | 67 | 296 | 14191 |
Mohammadreza Hojat | 61 | 250 | 16948 |
David J. Whellan | 60 | 269 | 16592 |
Paul F. Bray | 60 | 191 | 11632 |
Albert J. Wong | 57 | 111 | 13275 |
Makarand V. Risbud | 56 | 152 | 12069 |
David Madigan | 55 | 219 | 26042 |
Robert L. Brent | 49 | 325 | 10672 |
Joseph S. Gonnella | 47 | 140 | 10718 |
L. Fernando Gonzalez | 46 | 213 | 5994 |
Glenn L. Radice | 46 | 75 | 6883 |